Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Taiwan's TWi Biotech to Start Clinical Trial of Gout Treatment

publication date: Dec 12, 2014
TWi Biotechnology, a subsidiary of Taiwan's TWi Pharmaceuticals, has received permission to begin a Taiwan-US Phase II trial of a novel treatment for gout and high blood uric acid levels. Both the US and Taiwan FDAs approved a protocol for the trial, which will test TWi's AC-201 controlled-release oral formulation of an Interleukin-1Beta inhibitor. TWi has already successfully completed a US-Taiwan Phase II trial of AC-201 among patients with type 2 diabetes. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital